Results: Among 273 Enterococcus isolates, 27 and 2 VRE isolates, respectively, were XDR and PDR and eight isolates had BLIS activity against the indicator strain. One of these isolates, identified as E. faecium strain DSH20 based on its phenotypical and biochemical properties, as well as its 16S rRNA gene sequence, had potent BLIS production against all 29 VRE strains, but had no activity against MRSA, P. aeruginosa, Klebsiella, Acinetobacter, and E. coli strains. It was heat stable up to 121 C for 15 minutes (autoclave condition), active within the pH range of 3e9 and had UV stability, but its activity disappeared by treatment with proteinase K, pepsin, and trypsin, demonstrating its proteinaceous nature. It was designated as an approximately 35 kDa peptide using the sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) method. Conclusion: This peptide is a potential agent for use as an alternative antibacterial agent for the treatment of drug-resistant strains of VRE infection.
Introduction
The appearance and spread of antibiotic-resistant bacteria are serious problems in public health worldwide. 1, 2 For example, pandrug-resistant (PDR) isolates were defined as non-susceptible to all agents in all antimicrobial categories based on the European Centre for Disease Prevention and Control (ECDC) and the Centers for Disease Control and Prevention (CDC) definitions. 3 Therefore, these strains that are resistant to all tested antibiotic agents lead to curative failure of therapy and are serious threats to the patient's safety. Vancomycin-resistant Enterococcus (VRE) has developed a resistance to most commonly used antibiotics and there are currently very few antibiotics that can be used to treat these infections. New strategies for controlling these bacteria are urgently needed and the discovery of new antimicrobial agents, such as bacteriocin and bacteriocin-like inhibitory substance (BLIS), may help in keeping down the development of these infections. 1 Bacteriocins, secondary metabolites produced by various microorganisms, have bactericidal activity directed against species that are usually closely related to the producer microorganisms. 4e6 One of the critical limitations to the use of bacteriocins as antimicrobial and biopreservative agents, is their narrow spectrum of action. 7 The objective of this study was the isolation and characterization of broad spectrum BLIS active against PDR strains of VRE.
Materials and methods

Characterization and identification of bacteria from clinical specimens
Bacteria recovered from clinical specimens were identified by standard biochemical methods. 8 The samples were cultured on blood agar (purchased from Himedia Company, Mumbai, Vadhani Industrial Estate, India), the plates were incubated at 35 C for 24 hours and the pure isolates were characterized and identified according to Gram stains and biochemical tests, such as catalase reaction, presence of pyrrolidonyl arylamidase (PYR), growth on bile aesculin agar and 6.5% NaCl media.
Antimicrobial categories and agents used to define acquired resistance profiles in Enterococcus sp.
To define the acquired resistance profiles of Enterococcus isolates, antimicrobial categories and agents were used as shown in Table 1 , according to ECDC and CDC definition. 3 A multidrug-resistant (MDR) isolate was defined as being non-susceptible to at least one agent in three or more antimicrobial categories. An extensively drug-resistant (XDR) isolate was defined as being non-susceptible to at least one agent in all but two or fewer antimicrobial categories (i.e., bacterial isolates remain susceptible to only one or two categories). Non-susceptibility to all agents in all antimicrobial categories (i.e., no agents tested as susceptible) was defined as PDR Enterococcus. Thus, a bacterial isolate that is characterized as XDR will also be characterized as MDR and similarly, an XDR bacterial isolate 
Quinupristin-dalfopristin
Tetracycline Doxycycline Minocycline would have to be further defined as PDR. For example, an isolate that is just sensitive to gentamicin (belongs to the aminoglycosides category), imipenem (belongs to the carbapenems category) and linezolid (belong to the oxazolidinones category) but is resistant to other agents, is a PDR strain. An isolate that is just sensitive to linezolid and is resistant to all other agents, is an XDR isolate (and also PDR) and an isolate that is resistant to all agents mentioned in Table 1 , is a PDR isolate (and also MDR and XDR). 3 
Antimicrobial agents screening
For the antimicrobial potency production assay, a qualitative bioassay was performed using the spot-on-lawn method as follows: a medium consisting of trypticase soy broth supplemented with 0.6% yeast extract (TSBYE) without glucose and 1.5% agar prepared and spotted with 2 mL of isolated strains, was incubated overnight at 30 C for 24 hours. The incubated agar plates were overlaid with a softagar medium seeded with 10 7 /mL different VRE bacteria and E. faecalis ATCC 29212, that were tested to determine the VRE antimicrobial spectrum as indicator. For inhibition area observation the overlaid plates were incubated overnight and a clear inhibition area of 3 mm in diameter was reported as positive.
Antimicrobial agents production assay from fermentation broth by cell-free supernatant
Colonies showing inhibition activity were subcultured into 10 mL of TSBYE medium and incubated at 30 C for 24 hours. Then, the broth cultures were inoculated in a 2 L flask containing 500 mL TSBYE without glucose and incubated at 30 C for 24 hours in a rotary shaker with agitation at 180 rpm. Supernatant in the fermentation broth was separated by centrifugation at 13,000 g for 10 minutes at 12 C and adjusted to pH 7 with 5 M NaOH. Supernatant was exposed to 100 C for 5 minutes and then filtered using a 0.45 mm-pore-size filter. Some of this supernatant (20 mL) was spotted in BHI agar seeded by E. faecalis ATCC 29212 as the indicator. For control, TSBYE medium without glucose and bacteria adjusted to pH 7 with 5 M NaOH and exposed to 100 C for 5 min was used.
Effect of BLIS on the hospital-isolated bacteria
The antimicrobial effect of BLIS of the best producer was investigated on most common hospital-isolated pathogen bacteria, using the spot-on-lawn method as mentioned above. These isolates were identified using standard methods on the basis of their morphological, culture, and biochemical characteristics.
Growth kinetics and BLIS biosynthesis
The maximum BLIS production time in the Enterococcus strain that showed the best inhibitory effect on growth of E. faecalis ATCC 29212 as the indicator strain, was estimated using bacterial growth curves, based on a method described by Mirhosseini et al. 6 The antibacterial activity was calculated using a critical-dilution micromethod, by assaying serial two-fold dilutions of cell-free culture supernatants against E. faecalis ATCC 29212. As described above, cell-free culture supernatants were prepared. Effects of pH, heat, degenerative enzymes, and exposure to UV light on BLIS Effects of pH, heat, degenerative enzymes, and exposure to UV light on BLIS activity were tested. To monitor the changes in antimicrobial activity after these treatments, the qualitative spot-on-lawn bioassay, as described above, was used with E. faecalis ATCC 29212 as the indicator. For investigation of BLIS stability to temperature, pH and various degenerative enzymes containing proteinase K (pH 7.0), trypsin (pH 7.0) and pepsin (pH 3.0), the method explained by Mirhosseini et al 6 was used. The effect of UV light on BLIS activity was determined as follows: 10 mL of filter-sterilized cell-free supernatant, in a sterile Petri dish, was exposed to UV irradiation at a distance of 25 cm for 5, 10, 15, 20, 25, and 30 minutes. After each time interval, BLIS activity was analyzed by the critical-dilution micromethod as mentioned above.
BLIS molecular weight estimation by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and partial purification
For BLIS isolation and partial purification, the best BLIS producer was cultivated in TSBYE for 24 hours at 30 C and then purified partially as the method described by Mirhosseini et al. 6 Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) was used for estimation of BLIS molecular weight. After electrophoresis, the gel was fixated by treating with 20% isopropanol and 10% acetic acid for 2 hours. Then, the gel was removed and subdivided into two parts; one part was tested for antimicrobial activity and the second part was stained with Coomassie Brilliant Blue, containing the protein standards (low-molecular-mass range Sigma Marker protein standards).
Identification of BLSI producing isolate
The identification of the best BLSI producing isolate was initially carried out on the basis of its morphological, culture, and biochemical characteristics using standard methods; Bailey and Scott's Diagnostic Microbiology, 8 and then confirmed using 16S rRNA PCR using DNA extracts with the universal primers RW01 (5 0 -AAC TGG AGG AAG GTG GGG AT-3 0 ) and DG74 (5 0 -AGG AGG TGA TCC AAC CGC A-3 0 ) by the CinnaGene Company (Tehran, Iran).
Results
Identification of isolates
All of the 273 Enterococcus isolates were obtained from different clinical samples during 1 year. These isolates were Gram-positive, coccus-shaped, aerobes, non sporeformers, tested negative for the catalase enzyme, tested positive for the presence of PYR and had growth ability on bile-aesculin agar and 6.5% NaCl media.
Determination of acquired resistance profiles of Enterococcus spp.
To define the acquired resistance profiles in Enterococcus isolates, antimicrobial categories and agents were used as in Table 1 . Among 273 Enterococcus isolates, 212 (77.7%) were MDR, and were sensitive to meropenem, vancomycin, ampicillin, daptomycin, linezolid, quinupristin-dalfopristin and tigecycline but were resistant to other agents. In addition, among 273 Enterococcus isolates, 29 isolates were VRE, of which 27 were XDR and two were PDR.
BLIS production assay
Results showed that among the 29 VRE strains, eight isolates had antimicrobial activity showing large inhibition zones against E. faecalis ATCC 29212 as the indicator strain. One of these isolates identified as E. faecium strain DSH20 based on its phenotypical and biochemical properties, as well as its 16S rRNA gene sequence, had potent BLIS production against all other 29 VRE strains, in addition to the indicator strain. The BLIS production was confirmed in the neutralized supernatant of this isolate (data not shown). Table 2 demonstrated that BLIS of E. faecium strain DSH20 had no activity against Gram-negative bacteria containing P. aeruginosa, Klebsiella, Acinetobacter, and E. coli. In addition, no activity against MRSA strains was seen.
Effect of BLIS on the hospital-isolated bacteria
Growth kinetics and maximum bacteriocin biosynthesis
The growth curves and the profiles of BLIS production of the E. faecium strain DSH20 are shown in Fig. 1 . BLIS production was started in the mid-exponential phase of growth, and the maximum level (3000 AU/mL) was found at the late-stationary phase of growth. This strain exhibited the maximum antimicrobial activity against E. faecalis ATCC 29212 as the indicator strain after 31 hours of incubation at 30 C.
Sensitivity of BLIS to pH, heat, degenerative enzymes, and exposure to UV light Antimicrobial activity of Enterococcus faecium strain DSH20 was stable under heat and acidic/basic treatment, but was inactivated by proteinase K, pepsin, and trypsin enzymes Table 3 .
Estimation of BLIS molecular weight
Partially purified BLIS molecular weight was evaluated by SDS-PAGE, as shown in Fig. 2 . The gel stained with Coomassie Brilliant Blue showed protein bands and the molecular weight of partially purified BLIS from E. faecium strain DSH20 was estimated to be approximately 35 kDa (Fig. 2) . In addition, the SDS-PAGE of BLIS, overlaid with E.
faecalis ATCC 29212 as the sensitive indicator organism, showed a clear inhibition zone after 24 hours at 30 C ( Fig. 3 ).
Discussion
Enterococci are prominent bacteriocin producers due to production of diversity bacteriocins (enterocins). 10e12 They produce a wide group of structurally diverse antimicrobial peptides, some of which are atypical and different from known bacteriocins. 10 Despite these wide studies about bacteriocins production in Enterococcus isolates, there are rare studies about bacteriocins production in Enterococcus that have broad spectrum activity against PDR strains of VRE; there are no antibiotics for the treatment of these strains. Recent emergence of these pathogen bacteria has become a major clinical problem mobilizing the search for new potent antimicrobial agents. 1,2 Aunpad and Na-Bangchang 11 isolated pumilicin 4, a novel bacteriocin from Bacillus pumilus strain WAPB4 with anti-MRSA and anti-VRE activity, and Yamashita et al, 16 isolated bacteriocin 51 (Bac 51) from vancomycin-resistant E. faecium VRE38 that was active against E. faecium, E. hirae, and E. durans. In this study, Enterococci were isolated from different clinical samples and screened for broad spectrum bacteriocin production. One Enterococcus isolate identified as E. faecium strain DSH20 had potent BLIS production against all tested VRE strains, in addition to the indicator strain. BLIS produced by E. faecium strain DSH20 inactivated by proteinase K, pepsin, and trypsin enzymes, provided evidence for its proteinaceous nature, showed stability at a wide range of pH values from pH 3.0e9.0 at 30 C, was heat stable even after heating at 100 C for 5 minutes and kept at 75% in autoclave conditions (121 C for 15 minutes). In addition, the BLIS retained its activity after 30 minutes of exposure to UV light, which is the first report for this isolate. During the stationary phase of growth, the maximum levels of antimicrobial activity were determined according to findings by others. 1, 6 The molecular weight of this BLIS was approximately 35 kDa. Some other bacteriocins produced by strains from the Enterococcus genus, like pumilicin 4 isolated by Aunpad and Na-Bangchang, 11 as determined by mass spectrometry, was 1994.62 Dalton, have molecular weights ranging between 7 and 20 kDa and therefore most of these reported bacteriocins have molecular masses lower than that of our BLIS. This BLIS seems to be is a novel BLIS with a high molecular weight and it needs further identifying using a method such as MALDI-TOF; the potential gene encoding this BLIS needs to be provided.
Ideal physicochemical properties of this BLIS and its broad range of activity against VRE isolates, strongly suggests its use in preserving a wide range of foods or in pharmaceutical compositions that require heating during preparation, and as an alternative antibacterial agent for treatment of drug-resistant strains of VRE infection.
